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The high prevalence and chronicity of chronic obstructive pulmonary disease (COPD) imply that many of these 
patients are treated and controlled in primary-care centres, often without contact with specialized pneumologist care. 
We conducted the present study to evaluate the treatment administered in stable and exacerbated COPD in 
GP-setting clinics and to investigate which factors could be associated with the different prescriptions. 
This is a cross-sectional observational study of ambulatory COPD patients. General practitioners (n=201) were 
selected throughout Spain by regionally stratified sampling. We recorded the physician-reported prescription drug 
use in ambulatory treatment of stable COPD and acute exacerbations of COPD through a standard questionnaire. 
Factors independently associated with the prescription of drugs were ascertained by multiple logistic regression 
analysis. 
Of 1078 questionnaires reviewed, 1001 fulfilled quality criteria. There were 878 men (88%) and 123 women (12%); 
777 (78%) were smokers or ex-smokers with a mean age of 68 years. Mean FEV, was 47% predicted (% pred.) 
(SD= 13%). The median number of exacerbations was two per year (range=O-16). Regular treatment for COPD was 
received by 878 (88%): the most commonly used drugs were inhaled ,&agonists (71%), theophyllines (53%) and 
inhaled corticosteroids (ICs) (SO”!), followed by mucolytics (25%), ipratropium bromide (23%), and oral cortico- 
steroids (OCs) (4%). Treatment for exacerbations included inhaled bronchodilators (90%), antibiotics (89%), ICs 
(71%) and OCs (43%). 
Impairment of FEV, was the factor most strongly associated in multiple regression analysis with increasing drug 
prescription in stable COPD, except for mucolytics, while the number of previous acute exacerbations was the main 
factor associated with exacerbation treatment except for OCs, the use of which was associated with more impaired 
pulmonary function. 
A significant number of the treatments prescribed in primary care for stable and exacerbated COPD do not follow 
current recommendations. Impairment in FEV, is the factor most strongly associated with increasing prescription in 
stable COPD and the number of previous exacerbations is the main factor associated with exacerbation treatment. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) has a 
very high prevalence in developed countries. It is estimated 
that approximately 46% of adult white men and l-3% 
of adult white women suffer from emphysema or chronic 
airflow obstruction in the U.S.A. (1). Similarly, recent 
studies in Spain have shown a 6.4% prevalence of COPD 
among men between the ages of 35 and 65 years 
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(2), and a 9% prevalence among individuals of both 
sexes aged between 40 and 70 years using the European 
Respiratory Society (ERS) spirometric criteria of COPD 
(3). The high prevalence and chronicity of COPD imply 
that many of these patients are treated and controlled in 
primary-care centres, often without contact with specialized 
pneumological care, which may explain why on occasions 
the usual procedure of diagnosis and treatment of these 
patients does not follow the recommendations established 
by different scientific societies (4-7). In this respect, and 
as an example, a recent survey showed that only 3-28% 
of general practitioners (GPs) in different countries in 
Europe follow national guidelines in the treatment of lower 
respiratory tract infections (8). 
The present study was conducted to identify the usual 
patterns of treatment of COPD patients controlled in 
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primary-care centres, both in the stable phase and during 
exacerbations, and to investigate which factors could be 
associated with the different prescriptions. 
Methods 
SURVEY DESIGN 
We performed a cross-sectional observational study of 
ambulatory COPD patients. The study was conducted 
between 1 October 1994 and 30 May 1995 in general 
practices located throughout Spain. 
We selected 201 GPs by regionally stratified sampling. 
The inclusion criterion for the study was easy access to 
spirometry which fulfilled the ATS criteria (9) either in 
their own practice or in a reference hospital. Data were 
sought for the first eight consecutive adults seen in whom 
the GP considered the diagnosis to be COPD. This clinical 
diagnosis was based on the GP’s judgement but had to be 
confirmed by a spirometric test which displayed at least a 
forced expiratory volume in 1 s (FEV,) of ~80% of pre- 
dicted values and an FEV, to forced vital capacity (FVC) 
ratio of ~70%. The examination had to be performed in a 
stable phase, at least 1 month after recovery from an 
exacerbation and not more than 6 months from the data of 
inclusion in the study. 
Exacerbations were defined in terms of symptoms 
according to Anthonisen et al. (10). Briefly, a patient was 
considered to be exacerbated when he/she presented with 
increased dyspnoea, increased sputum volume and/or 
sputum purulence. Exclusion criteria included diagnosed 
cystic fibrosis, asthma or severe bronchiectasis. 
The validity of the diagnoses of both COPD and exacer- 
bations was not assessed further than by the analysis of 
consistency and validity of the questionnaires and spiro- 
metric data, since the GP’s opinion was the salient point. 
DATA COLLECTION 
Data were collected through a standard questionnaire 
which covered demographical data, pulmonary risk factors, 
comorbid illnesses, COPD characteristics, drug usage in the 
stable phase and during exacerbations and the number and 
characteristics of exacerbations of COPD. 
The questionnaires were completed by the GPs at the 
time of the patient’s medical visit. All questionnaires and 
spirometry data submitted were reviewed and rated for 
quality by two experienced pneumologists (M.M. and 
C.M.), who filtered inconsistencies. For a submitted 
questionnaire to be considered valid it had to include: 
1. complete demographical data; 2. complete spirometric 
data; and 3. data on treatment administered either in stable 
phase, during an exacerbation, or both. Questionnaires 
containing inconsistencies, as well as those with missing or 
out-of-range values, were not included in the final analysis. 
A specific database was designed ad hoc and informa- 
tion recorded through a process of double-entry and 
cross-comparison of data. 
STATISTICAL ANALYSIS 
Descriptive statistical analysis was performed. The 
Student’s t-test and Snedecor F (ANOVA) were used for 
comparisons between means. The Mantel-Haenszel chi- 
squared test was used to assess significant trends between 
the use of different treatments and the progressive impair- 
ment in pulmonary function represented by the FEV, 
percentage predicted (% pred.), categorized into severe 
(<40%), moderate (40-59%) or mild (>60%). 
Multiple logistic regression analysis was performed to 
ascertain which factors were independently associated with 
the prescription of drugs for stable COPD, and with the 
prescription of different treatments for acute exacerbations. 
Factors included in the model for stable COPD were age, 
sex, FEV, % pred. categorized into the three categories as 
mentioned above and presence or absence of chronic mucus 
hypersecretion (CMH), defined as the emission of more 
than 30 ml of expectoration daily. 
Factors included in the model of antibiotic treatment for 
exacerbations of COPD comprised the same variables plus 
the number of exacerbations suffered the previous year 
(PAE, previous acute exacerbations) categorized into five 
ordinal categories: 0, 1, 2, 3 and >3. 
A difference of PcO.05 was considered significant. The 
SAS statistical software (SAS Institute, Cary, SC, U.S.A.) 
was used for analysis. 
Results 
POPULATION CHARACTERISTICS 
A total of 201 GPs participated in the study. As not all GPs 
included the expected number of patients, information on 
1078 patients was collected during the study period (67.3% 
of the expected sample). Seventy-seven patients were 
excluded from the study, either because spirometric data 
showed no airflow obstruction or because the question- 
naires did not fulfil the required quality criteria. Thus, 1001 
patients were included of whom 878 were men (88%). The 
main characteristics of the population are summarized in 
Table 1. 
A great number of patients displayed severe pulmonary 
function impairment: 372 (37%) showed FEV, (%) below 
40% pred., 424 (42%) between 40 and 59% and only 205 
(20%) were over 60%. 
The mean age of the population was 68 f 9 years, with a 
mean symptom duration of 14 & 10 years. The median 
number of exacerbations was two per year; 309 patients 
(31%) suffered three or more exacerbations in 1 year. With 
respect to admissions, the median was 0.24 per patient per 
year; 832 patients (83%) were not admitted during the 
previous year and only 41 (4%) were admitted more than 
once during that period. 
TREATMENT OF STABLE COPD 
Eighty-eight per cent (87811001) of patients were receiv- 
ing treatment for COPD on a regular basis. Treatments 
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TABLE 1. Characteristics of 1001 ambulatory patients with COPD 
All 
FEV, >60% 40-59 
n = 205 (20%) n = 424 (42%) 
Mean i SD 
<40% 
n=372 (37%) 
Age (years) 
Male (%) 
Smoking 
Current or ex-smoker (%) 
Pack year 
FVC (1) 
FVC (% pred.) 
FEV, (1) 
FEV, (% pred.) 
FEV, FVC - ’ (%) 
Symptom duration (years) 
Exacerbations last (n) year 
68 *9 66Zt 11 68 f 9 68 It 9 
878 (88) 171 (83) 371 (87) 336 (90) 
777 (78) 154 (75) 326 (77) 297 (80) 
41 i29 37 zt 24 41 l 31 43 ZIL 29 
2.38 f 0.77 2.97 zt 0.74 2.44 f 0.64 1.97 f 0.67 
66% 19 83~t 17 68% 15 53* 15 
1.26 h 0.47 1.77 f 0.4 1.30 * 0.28 0.92 dc 0.36 
47Zt 13 67 z!z 5 49 * 5 321.4 
53& 11 60 f 7 54 f 8 47% 10 
14 * 10 ll& 10 14 * 10 14&9 
2+ 1.8 1.6 f 1.5 1.9 & 1.8 2.3 f 1.9 
All values are mean ?C SD. 
TABLE 2. Results of logistic regression analysis of factors associated with the prescription of 
treatments for stable COPD 
Dw No/yes Factor OR 95% CI P-value 
Inhaled &agonists 288/713 FEV, (% pred.) 0.55 0.45-0.68 0~0001 
(71%) CMH (no/yes) 0.74 0.55-0.99 0.04 
Theophyllines 4681533 FEV, (% pred.) 0.53 0.44-0.64 0.000 1 
(53%) Age I.02 1.00-l .03 0.004 
CMH (no/yes) 1.40 1.07-1.85 0.01 
Ipratropium bromide 7661235 FEV, (% pred.) 0.68 0.540.84 0.0006 
(23%) Gender (w/m) 1.88 1.063.26 0.03 
Mucolytics 7481253 CMH (no/yes) 1.88 1.36-2.55 0.000 1 
(25%) Age 1.02 1.00-l .04 0.005 
Inhaled corticosteroids 500/501 FEV, (% pred.) 0.64 0.540.77 0.000 1 
(50%) Age 1.01 1.00-l .02 0.04 
All factors with PcO.10 are shown in the table. 
administered for stable COPD were: inhaled j&-agonists 
(71%), theophyllines (53%), inhaled corticosteroids (10) 
(50%), mucolytic agents (25%), inhaled anticholinergics 
(23%) and oral corticosteroids (OCs) (4%). 
Factors independently associated with prescription of 
the different drugs are shown in Table 2. With the exception 
of mucolytics, the strongest association for all treatments 
was observed with the degree of FEV, impairment. CMH 
was significantly associated with the use of mucolytics 
and theophyllines (ORz1.88; 95% CI= 1.362.55 and 
OR= 1.40; 95% CI= 1.07-1.85, respectively), but inversely 
with inhaled &agonists (ORz0.74; 95% CI=O.55-0.99). 
Differences in prescriptions among the different groups of 
patients according to their functional impairment, together 
with the statistical significance of the Mantel-Haenszel 
chi-squared tests, are shown in Fig. 1. 
TREATMENT OF ACUTE EXACERBATIONS OF 
COPD 
Information on treatment administered during the last 
exacerbation was available for 886 patients (88%). Treat- 
ments were evaluated either when they were started or 
when they were increased in dosage with respect to the 
stable condition. Treatments administered were: inhaled 
bronchodilators, 90% (7971886); antibiotics, 89% (792/886); 
ICs, 71% (629/886); and OCs, 43% (3811886). 
Factors associated with prescription are shown in 
Table 3. In this case, FEV, was independently associ- 
ated only with the prescription of OCs, while the most 
important factor was the number of previous exacer- 
bations which was significantly associated with all 
treatments. 
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FIG. 1. Treatment administered for stable COPD in 1001 
patients. P-values obtained from Mantel-Haenszel chi- 
squared test. IB2, Inhaled &-agonist; The, theophyllines; 
IB, ipratropium bromide; Muc, mucolytics; ICs, inhaled 
corticosteroids. (0, FEV, ~40%; W, FEV, =4&59%; q 
FEV, >60%.) 
The different antibiotics administered for exacerbations 
were: coamoxiclav, 3 1% (247/792); cephalosporins, 22% 
(172/792); macrolides, 21% (17 11792); amoxicillin, 12% (971 
792); quinolones, 12% (95/792); and others, 1.2% (10/792). 
The distribution of antibiotics among the different degrees 
of COPD severity is shown in Fig. 2; only quinolones 
showed a different pattern of use, and were prescribed 
significantly more to patients with the most severe func- 
tional impairment. 
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FIG. 2. Antibiotics administered for acute exacerbations 
in 792 patients with COPD. P-values obtained from 
Mantel-Haenszel chi-squared test. A-cl, Amoxicillin- 
clavulanic acid; Cep, cephalosporins; Mac, macrolides; 
Amx, amoxicillin; Qui, quinolones. Key as in Fig. 1. 
Discussion 
The results of this study show that a significant number of 
patients with COPD treated in general practice have severe 
pulmonary function impairment. COPD treatment usually 
consists of a combination of inhaled &agonists and theo- 
phyllines, although approximately one-half of the patients 
receive ICs, oral theophyllines or both on a regular basis. 
Exacerbations are almost always treated with oral anti- 
biotics and inhaled bronchodilators, but less than half of 
TABLE 3. Results of the logistic regression analysis of factors associated with the prescriptions of 
treatments for exacerbated COPD 
Drug No/yes Factor OR 95% CI P-value 
Antibiotics 941792 PAE* 1.31 1~08-1~59 0.006 
(89%) 
Bronchodilators 891797 PAE* 1.23 0.99-1.55 0.05 
(90%) 
Inhaled corticosteroids 2571629 PAE* 1.52 1.30-1.80 0~0001 
(71%) FEV, (% pred.) 0.79 0.62-1.02 0.07 
Oral corticosteroids 505/38 1 FEV, (% pred.) 0.46 0.340~61 0.000 1 
(43%) PAE* 1.63 1.39-1.93 0.000 1 
Age 1.02 0.99-1.04 0.05 
All factors with PcO.10 are shown in the table. 
*PAE, number of previous acute exacerbations. 
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the patients receive a short course of OCs. The factor 
most strongly associated with prescription in stable COPD 
is the degree of FEV, impairment, except in the case of 
mucolytics which are only significantly associated with the 
presence of CMH. In contrast, the most important factor 
associated with treatment of exacerbations is the number of 
previous exacerbations, while FEV, is only independently 
associated with the prescription of a short course of OCs. 
The conclusions of this study should be interpreted with 
caution owing to the number of patients recruited, 67% of 
those expected. Despite repeated contacts with GPs, some 
failed to include the expected number of individuals. How- 
ever, the large number of GPs surveyed from different 
geographical areas of Spain contributed additional interest- 
ing information to the existing surveys on treatment 
performed in other countries (8,ll). Furthermore, unlike 
these latter surveys, our sampling method was based on 
obtaining information prospectively under real conditions 
and with real patients, instead of reporting prescription 
habits in a questionnaire. 
It is noteworthy that our series included 22% non- 
smokers. Although current definitions of COPD do not 
exclude non-smokers and most surveys on COPD include a 
variable proportion of such individuals, it is possible that a 
small number of these patients were actually suffering from 
anther obstructive lung disease. Because the present study 
focuses on GPs’ attitudes as to what they diagnose as 
COPD, this possible mis-diagnosis should not affect the 
results. 
We observed that one-third of the patients reported in 
our study and controlled in general practice had FEV, 
below 40% pred. and form a subgroup of patients particu- 
larly prone to severe complications. For this reason it is 
very important to analyse the real management of COPD 
patients in the GP setting; this was demonstrated by a 
recent Spanish study which showed that only 36% of GPs 
performed pulmonary function tests in obstructive patients 
and only 35% regularly followed guidelines for the manage- 
ment of asthma or COPD (12). Similar poor results regard- 
ing the use of spirometry by primary-care physicians were 
observed in a recent study in Canada (12). However, there 
are even more pessimistic results. A recent European survey 
showed that only 4% of a sample of Spanish GPs and 3% of 
French GPs followed national guidelines for the antibiotic 
treatment of lower respiratory tract infections, while 
between 24 and 28% of GPs in other European countries 
declared that they followed current recommendations (8). 
Most of the patients reported here (88%) received regular 
treatment for their respiratory disease. The more commonly 
used drugs were &agonists, theophyllines and 10, while 
only 23% received inhaled anticholinergics, which were 
prescribed more frequently in men than in women. Inter- 
estingly, this figure is almost identical to the 25% use 
of ipratropium bromide in stable COPD observed in an 
ambulatory setting in a Canadian study (13). This contrasts 
with the suggestion that anticholinergics are first-line drugs 
for the treatment of stable COPD (14) and most guidelines 
recommend their use alone or in combination with inhaled 
/&-agonists as a first-stage treatment (4,5,7). It is interesting 
to note the extensive use of theophyllines in Spain 
compared with other countries such as the U.K.. where in 
a recent population-based study none of the patients 
identified as suffering from COPD were taking theo- 
phyllines (15). However, our results are similar to the 45% 
use of methylxanthines in COPD patients involved in an 
international study in six European countries and New 
Zealand (16); interestingly, the patients described therein 
were very similar to those in the present study, with a mean 
FEV, of 45% pred. compared to 47% pred. in ours. This 
concurs with our observation that ventilatory impairment is 
associated with a more extensive use of this drug. Further- 
more, increased age is associated with more theophylline 
use, possibly due to the advantage of oral administration 
which is preferred for the elderly who tend to have more 
problems with inhaled medication. 
Another aspect of treatment is that one-quarter of our 
population were regularly taking mucolytics irrespective of 
their functional impairment, although all guidelines agree 
that widespread use of these agents cannot be recom- 
mended on present evidence (47). Again, their use is 
associated with increased age, probably due to the oral 
route of administration. Moreover, the increasing use of 
mucolytics associated with mucus hypersecretion suggests 
that GPs really believe in their questioned biological action. 
The extensive use of ICs in stable COPD was surprising. 
The usefulness of ICs in this indication is under debate. To 
date, some studies have shown an improvement in either 
spirometric parameters or in the decline of pulmonary 
function in small groups of patients, particularly those with 
positive bronchodilator response (17,18), but this improve- 
ment is evidently only in approximately 25% of patients 
(18). Nevertheless, one-half of the patients in the present 
study were receiving ICs. However, this is not unique; 
two-thirds of the COPD patients in the study of Jones et ul. 
(16) were also receiving ICs, and up to 41% in the study of 
Jackevicius et al. (13). Unfortunately, we lack information 
on the use by GPs of any objective criteria other than FEV, 
impairment for selecting the patients who were prescribed 
ICS. 
There were also widespread use of ICs for treatment of 
exacerbations of COPD. Seventy-one per cent of patients 
received them in this situation, a higher percentage than the 
53% observed in the Canadian study (13). In contrast, only 
43% of patients were prescribed a short course of OCs, even 
considering that the patients described here had moderate 
to severe impairment in pulmonary function. The use of 
short-course OCs has appeared to be sufficient to eliminate 
bronchial obstruction in mild to moderate exacerbations of 
COPD in ambulatory general practice (19) and it has shown 
to be effective as an outpatient treatment of exacerbations 
in severe COPD patients (20). OCs were the only treatment 
administered in exacerbations that was significantly associ- 
ated with more severe impairment in pulmonary function. 
The use of antibiotics in exacerbations of COPD remains 
controversial. Some studies have failed to demonstrate any 
benefit derived from antibiotics on recovery in ambulatory 
patients with mild to moderate COPD (19); moreover, the 
study by Anthonisen et al. (10) showed antibiotics to be 
superior to placebo in severe exacerbations, while no differ- 
ences in outcome were observed in mild to moderate 
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exacerbations. Eighty-nine per cent of the patients reported 
here received antibiotics irrespective of the severity of their 
illness or exacerbation, somewhat below the 99% observed 
in the data from Spain in the study by Huchon et al. (8) and 
very similar to the 92% observed by Davey et al. (21) in 
patients with suspected lower respiratory tract infection. 
The most frequently used antibiotic in our series was 
coamoxiclav (31% of cases), while in series from the U.K. 
this antibiotic accounted for only 6 (21) or 1% (22) of 
treatments. The opposite occurred with amoxicillin which 
was prescribed in 47 and 80% of patients in the latter 
studies, but in only 12% of our population. Although 
differences between these studies may be due in part to 
patient selection (both U.K. studies included adult patients 
with lower respiratory tract infections, a population with 
less severe impairment of pulmonary function than ours), 
our present data do not support this idea. The use of all 
antibiotics was equally distributed among patients with 
different degrees of functional impairment; the only 
exception was quinolones, which were more often pre- 
scribed to those patients more severely impaired. Only in 
this last case are our results in agreement with some 
guidelines that have established different degrees of COPD 
severity to orient antibiotic treatment of exacerbations 
(6X0. 
A possible bias of the study stems from the selection of 
centres with easy access to spirometry. It can be reasoned 
that the sample presented here is composed of physicians 
with more facility for a proper care of respiratory patients, 
and even more interest in respiratory disease. In this case, 
the patterns of medical care presented here might be biased 
towards better care. 
In conclusion, the self-reported prescribing habits of GPs 
lag in part behind current guidelines and recommendations 
for treatment of COPD. COPD is an important public 
health problem and further studies are required to ascertain 
the real management of this disease in different settings. 
The results of these studies may assist us in designing 
strategies to improve the care of these patients at all levels 
of health care. 
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